Corbus Pharmaceuticals
Yahoo Finance • 4 months ago
After-Hours Gainers: Biotech Stocks Climb On Data Anticipation And Momentum Buying
(RTTNews) - U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinic... Full story
Yahoo Finance • 5 months ago
Corbus Pharmaceuticals Announces Pricing of Public Offering
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public offering of 4,744,... Full story
Yahoo Finance • 5 months ago
Corbus Pharmaceuticals Announces Proposed Public Offering
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares of its common sto... Full story
Yahoo Finance • 6 months ago
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
3.6 mg/kg dose generated ORR of 47.6% in HNSCC, 37.5% in cervical cancer and 55.6% in mUCCRB-701 continues to demonstrate a favorable safety and tolerability profileRegistrational studies planned to start in mid-2026Company to host an HNSC... Full story
Yahoo Finance • 6 months ago
InvenTrust Properties Breaks Below 200-Day Moving Average - Notable for IVT
In trading on Tuesday, shares of InvenTrust Properties Corp (Symbol: IVT) crossed below their 200 day moving average of $28.65, changing hands as low as $28.55 per share. InvenTrust Properties Corp shares are currently trading up about 0.... Full story
Yahoo Finance • 8 months ago
Corbus Pharma's Q2 Net Loss Widens
(RTTNews) - Corbus Pharmaceuticals Holdings, Inc. (CRBP), a U.S.-based pharmaceutical company, reported a wider loss in the second quarter. The company reported a net loss of $17.7 million or $1.44 per share in the second quarter of 2025,... Full story
Yahoo Finance • 10 months ago
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab
Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and cervical cancerData update on schedule fo... Full story
Yahoo Finance • 10 months ago
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium
NORWOOD, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fire si... Full story
Yahoo Finance • 11 months ago
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate updat... Full story
Yahoo Finance • 11 months ago
Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of... Full story
Yahoo Finance • last year
Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity
CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled for completion Q3 2025 and Phase 1b dose-ra... Full story
Yahoo Finance • last year
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025
Study mirrored 4 highest doses used in China dose escalation study presented at ASCO 2024 Safety, tolerability and PK comparable to China dataset with no DLTs observed in either study Low levels of peripheral neuropathy and skin toxicity o... Full story
Yahoo Finance • last year
Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU
NORWOOD, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that the abstract for its first-in-human dose escalation clinical study conducted in the... Full story
Yahoo Finance • 2 years ago
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Data from dose escalation study for CRB-701, a Nectin-4 ADC to treat solid tumors, on track for release in early 2024 along with start of U.S./EU StudyIND Submission for CRB-601, an αvβ8 Monoclonal Antibody to treat solid tumors, on track... Full story
Yahoo Finance • 2 years ago
Corbus Pharmaceuticals Presents Results of Two Pre-Clinical Studies on its Anti-αVβ8 Monoclonal Antibody (CRB-601) at the 2023 SITC Annual Meeting
NORWOOD, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company, today announced that results from two pre-clinical studies on its CRB-601 a... Full story
Yahoo Finance • 2 years ago
Corbus Pharmaceuticals Announces Publication of Data for its Novel Cannabinoid Type-1 Receptor Inverse Agonist in a Pre-Clinical Model of Obesity Along with Presentations at Obesity Week 2023
CRB-913 is a novel highly peripherally restricted CB1 inverse agonist with potent monotherapy efficacy in DIO mouse modelWeight loss and related outcomes markedly enhanced in combination with tirzepatide, semaglutide or liraglutide NORWOO... Full story
Yahoo Finance • 2 years ago
Corbus Pharmaceuticals Presents the First Pre-Clinical Characterization of its Next Generation Nectin-4 ADC CRB-701
CRB-701 demonstrates a differentiated nonclinical profile relative to enfortumab vedotin Early dose escalation clinical data supports differentiating features established pre-clinicallyThe company on schedule to initiate its US study in Q1... Full story
Yahoo Finance • 3 years ago
Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023
NORWOOD, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that it will host a Virtual ‘Meet the Expert’ event on the... Full story
Yahoo Finance • 3 years ago
Corbus Pharmaceuticals Set to Join Russell Microcap® Index
NORWOOD, Mass., June 26, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that the Company is set to join the Russell Microcap® Index at th... Full story
Yahoo Finance • 3 years ago
Corbus Pharmaceuticals Data on CRB-601 avβ8 Blocking Antibody Accepted for Presentation at the America Association for Cancer Research Annual Meeting
NORWOOD, Mass., March 14, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that an abstract highlighting pre-clinical data for CRB-601, its... Full story
